Gilead Sciences

Gilead Sciences  (NASDAQ:GILD) reported Q2 non-GAAP diluted earnings  of $1.34, down from $1.58 a year earlier. Analysts surveyed by Capital IQ expected $1.64. Revenue for the quarter ended June 30 was $6.60 billion, up from $6.26 billion a year earlier. Analysts surveyed by Capital IQ expected $6.45 billion. The company said it expects full-year 2023 non-GAAP diluted EPS of $6.45 to $6.80, down from the previous outlook of $6.60 to $7. Analysts surveyed by Capital IQ expect $6.73. The company expects product sales for the year of $26.3 billion to $26.7 billion, compared with previous outlook of $26.0 billion to $26.5 billion. Gilead said its board maintained a quarterly dividend of $0.75 per share, payable on Sept. 28 to stockholders of record on Sept. 15.

Gilead Sciences (NASDAQ:GILD) provid For 2023, Gilead retains non-GAAP diluted EPS of between $6.60 and $7 on total product sales between $26 billion and $26.5 billion, both unchanged from the previous guidance. Analysts polled by Capital IQ expected a normalized EPS of $6.84 on revenue of $26.73 billion.

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $1.37 per share which missed the analyst consensus estimate of $1.54。 The company reported quarterly sales of $6.35 billion which beat the analyst consensus estimate of $6.33 billion。

Gilead Sciences’ (NASDAQ:GILD) fourth-quarter 2022 revenue was $7.4 billion, versus analysts’ expectations of $6.64 billion. Veklury’s revenue in the fourth quarter was $1.00 billion, compared with analysts’ expectations of $533.2 million. Product sales are expected to be $26-26.5 billion in 2023, compared with analysts’ expectations of $25.38 billion. Veklury is expected to generate about $2 billion in revenue in 2023, compared with analysts’ expectations of $1.4 billion.